ライフサイエンスコーパス: hepatitis B e antigen

1 were associated with a higher prevalence of hepatitis B e antigen.

2 for hepatitis B surface antigen, HBV DNA, or hepatitis B e antigen.

3 s than nonresponders were still negative for hepatitis B e antigen (94% vs. 40%; P < 0.001) and hepat

4 The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA conce

5 e and 44% had hepatitis B virus DNA testing; hepatitis B e antigen and hepatitis B e antibody were te

6 l activity as evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV) DNA.

7 ic response (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 52 of t

8 , 31 (30%) responded to therapy with loss of hepatitis B e antigen and viral DNA from serum.

9 Seventeen percent to 33% experience loss of hepatitis B e antigen, and 53% to 56% have a histologic

10 transaminase (ALT) levels, disappearance of hepatitis B e antigen, and improvement in liver histolog

11 Ag loss with the appearance of antibodies to hepatitis B e antigen (anti-HBe) at the end of PEG-IFN t

12 A in serum and 45 (87%) had detectable serum hepatitis B e antigen before treatment.

13 B virus infection and propose mechanisms for hepatitis B e-antigen clearance, subsequent emergence of

14 positions of the AUG codon severely impaired hepatitis B e antigen expression (P < 0.001).

15 rican and core promoter mutations diminished hepatitis B e antigen expression in an additive manner.

16 Reduction in hepatitis B e antigen expression may contribute to accel

17 this study was to determine their effect on hepatitis B e antigen expression.

18 erum aminotransferase levels, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), h

19 gen (HBsAg) positive, and 61% had detectable hepatitis B e antigen (HBeAg) and HBV DNA when treatment

20 omoter (BCP) mutants and studied kinetics of hepatitis B e antigen (HBeAg) and hepatitis B surface an

21 Spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV

22 death ligand (PD-L)1, and the suppression of hepatitis B e antigen (HBeAg) and surface antigen (HBsAg

23 ith spontaneous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance.

24 2.3, 95% confidence interval [CI] 1.7-3.2), hepatitis B e antigen (HBeAg) clearance/loss (RR = 2.1,

25 ne therapy (100 mg/d) in 24 patients who had hepatitis B e antigen (HBeAg) despite 1 to 3 months of p

26 enhance viral genome replication and reduce hepatitis B e antigen (HBeAg) expression.

27 52 percent vs. 23 percent, P<0.001), loss of hepatitis B e antigen (HBeAg) in serum (32 percent vs. 1

28 ages, 14-39 y); 9 patients were positive for hepatitis B e antigen (HBeAg) in the immune-tolerant pha

29 Hepatitis B e antigen (HBeAg) is a secreted version of h

30 The function of the hepatitis B e antigen (HBeAg) is largely unknown because

31 rus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chro

32 Undetectable serum HBV DNA and hepatitis B e antigen (HBeAg) loss were significantly mo

33 isease in one-third of patients with typical hepatitis B e antigen (HBeAg) positive chronic hepatitis

34 fected with CHB, among whom, 28.6% were also hepatitis B e antigen (HBeAg) positive.

35 gnificantly higher in subjects with maternal hepatitis B e antigen (HBeAg) positivity and who receive

36 depends on hepatitis B virus (HBV) genotype, hepatitis B e antigen (HBeAg) presence, persistently hig

37 The durability of hepatitis B e antigen (HBeAg) responses after a consolid

38 disease-related death (9.4% vs 0%; P = .03), hepatitis B e antigen (HBeAg) seroconversion (61.5% vs 2

39 Forty subjects with chronic hepatitis B and hepatitis B e antigen (HBeAg) seroconversion following l

40 Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by

41 It is unclear whether hepatitis B e antigen (HBeAg) seroconversion induced by

42 have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an

43 ated with a prolonged viremic phase, delayed hepatitis B e antigen (HBeAg) seroconversion, and an inc

44 irus replication, activity of liver disease, hepatitis B e antigen (HBeAg) seroconversion, and interf

45 ) precore/core gene mutations on spontaneous hepatitis B e antigen (HBeAg) seroconversion, HBV biosyn

46 eous and interferon alfa (IFN-alpha)-related hepatitis B e antigen (HBeAg) seroconversion.

47 In spontaneous hepatitis B e antigen (HBeAg) seroconverters, lower seru

48 Twenty-two percent were hepatitis B e antigen (HBeAg) seropositive; 20.4% (59/28

49 y was examined with respect to HBV genotype, hepatitis B e antigen (HBeAg) serostatus, and race.

50 study was to identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to ant

51 Hepatitis B e antigen (HBeAg) status and serum hepatitis

52 for treatment of chronic hepatitis B include hepatitis B e antigen (HBeAg) status, levels of hepatiti

53 e to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeA

54 Circulating hepatitis B e antigen (HBeAg) was found to distinguish t

55 onic HBV infection who were positive for the hepatitis B e antigen (HBeAg) were randomly assigned (2:

56 core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg(-) patients

57 aive and treatment-experienced children with hepatitis B e antigen (HBeAg)+ CHB were randomized to AD

58 ence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and cirrhosis.

59 Hepatitis B e antigen (HBeAg), encoded by the precore RN

60 visits and was independently associated with hepatitis B e antigen (HBeAg), HAART <2 years, CD4 <200

61 In contrast to hepatitis B e antigen (HBeAg), HBsAg was not a reliable

62 ollow-up examinations were tested for HBsAg, hepatitis B e antigen (HBeAg), serum hepatitis B virus (

63 mune active (IA), inactive carrier (IC), and hepatitis B e antigen (HBeAg)-negative (ENEG) hepatitis

64 A total of 641 hepatitis B e antigen (HBeAg)-negative and HBeAg-positiv

65 true for patients with the difficult-to-cure hepatitis B e antigen (HBeAg)-negative chronic hepatitis

66 Hepatitis B e antigen (HBeAg)-negative chronic hepatitis

67 A total of 1,068 Taiwanese hepatitis B e antigen (HBeAg)-negative HBV carriers with

68 Hepatitis B e antigen (HBeAg)-negative hepatitis is a cl

69 A total of 243 (69%) patients were hepatitis B e antigen (HBeAg)-negative of whom 15% had c

70 epatocellular carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative patients with an

71 n of nucelos(t)ide analog (Nuc) treatment in hepatitis B e antigen (HBeAg)-negative patients with chr

72 long-term nucleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chr

73 is B virus (HBV) DNA of 203 treatment-naive, hepatitis B e antigen (HBeAg)-negative patients with spo

74 d core promoter variants were more common in hepatitis B e antigen (HBeAg)-negative than in HBeAg-pos

75 udy of 379 nucleos(t)ide-naive patients with hepatitis B e antigen (HBeAg)-positive (n = 264) or HBeA

76 by PCR (<300 copies/mL, <57 IU/mL) in 91% of hepatitis B e antigen (HBeAg)-positive and -negative pat

77 Approximately 30% of hepatitis B e antigen (HBeAg)-positive and 40% of HBeAg-

78 48-week regimen of pegylated interferon for hepatitis B e antigen (HBeAg)-positive and HBeAg-negativ

79 been shown to be effective in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis

80 , open-label, multicenter, randomized trial, hepatitis B e antigen (HBeAg)-positive chronic hepatitis

81 Peginterferon (PEG-IFN) treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis

82 A limited number of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis

83 t 48 weeks in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis

84 phases: immune tolerance, immune clearance [hepatitis B e antigen (HBeAg)-positive chronic hepatitis

85 nes, HBIG was given to all 583 children with hepatitis B e antigen (HBeAg)-positive mothers and to 72

86 Patients were hepatitis B e antigen (HBeAg)-positive or HBeAg-negative

87 uation, being relatively higher in initially hepatitis B e antigen (HBeAg)-positive patients (62.5%,

88 Hepatitis B e antigen (HBeAg)-positive patients achieved

89 developing in 14 patients, including 76% of hepatitis B e antigen (HBeAg)-positive patients but only

90 Fifty-nine hepatitis B e antigen (HBeAg)-positive patients with gen

91 n about the benefit of antiviral therapy for hepatitis B e antigen (HBeAg)-positive patients with hig

92 in studies using nucleoside regimens and in hepatitis B e antigen (HBeAg)-positive patients.

93 Among hepatitis B e antigen (HBeAg)-positive samples, median t

94 This study compared rates of spontaneous hepatitis B e antigen (HBeAg)-positive to -negative sero

95 nts were recruited, of which 43 (61.4%) were hepatitis B e antigen (HBeAg)-positive.

96 Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B

97 uncated protein is secreted from the cell as hepatitis B e antigen (HBeAg).

98 code a secreted nonstructural protein called hepatitis B e antigen (HBeAg).

99 Maternal hepatitis B e-antigen (HBeAg) and high viral load have b

100 aged 18-55 years, who were treatment naive, hepatitis B e antigen [HBeAg] negative, anti-hepatitis D

101 of coinfections, HBV viral level, change in hepatitis B e antigen [HBeAg] status, genotype, HBV muta

102 expression constructs containing wild-type (hepatitis B e antigen [HBeAg]-positive) and precore muta

103 immunodeficiency virus or hepatitis B virus (hepatitis B e antigen [HBeAg]-positive) led the Centers

104 ents with HBV-related chronic liver disease (hepatitis B e antigen [HBeAg]-positive, n = 11; HBeAg-ne

105 31%) of the initially positive patients lost hepatitis B e antigen; hepatitis B surface antigen was u

106 develop mathematical models for the role of hepatitis B e-antigen in creating immunological toleranc

107 t the -5 and -2 positions moderately reduced hepatitis B e antigen levels (P < 0.001) to an extent co

108 ction, higher HBV DNA levels, lower rates of hepatitis B e antigen loss, increased cirrhosis and live

109 el to account for mechanisms responsible for hepatitis B e-antigen loss, such as seroconversion and v

110 ies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and

111 We analyzed data from 347 hepatitis B e antigen-negative and 238 hepatitis B e ant

112 we studied NK-cell phenotype and function in hepatitis B e antigen-negative chronic HBV patients eith

113 Hepatitis B e antigen-negative chronic hepatitis B (e-CH

114 )ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B.

115 ections, inactive HBV carriers, or untreated hepatitis B e antigen-negative patients with chronic inf

116 However, when we evaluated hepatitis B e antigen-negative patients with levels of H

117 Among hepatitis B e antigen-negative patients with low viral l

118 pping versus continuing antiviral therapy in hepatitis B e antigen-negative patients, monotherapy ver

119 ociated with higher rates of seroconversion (hepatitis B e antigen or hepatitis B surface antigen) co

120 m 347 hepatitis B e antigen-negative and 238 hepatitis B e antigen positive patients receiving tenofo

121 C was significantly higher in those who were hepatitis B e antigen positive, suggesting that antivira

122 FTC and were hepatitis B surface antigen and hepatitis B e antigen positive; 4 had cirrhosis.

123 At baseline, 91% of patients were hepatitis B e antigen-positive and 85% had prior exposur

124 d of January 2009 to March 2011, we enrolled hepatitis B e antigen-positive mothers with HBV DNA >6 l

125 es), use of peripartum antivirals (to 80% of hepatitis B e antigen-positive mothers), and population-

126 nuing versus continuing antiviral therapy in hepatitis B e antigen-positive patients who seroconverte

127 changes were easily detectable in the acute, hepatitis B e antigen-positive phase of infection, sugge

128 118 hepatitis B surface antigen (HBsAg)- and hepatitis B e antigen-positive pregnant women with HBV D

129 Maternal hepatitis B e antigen positivity but not hepatitis B imm

130 including 3 with YMDD variants, experienced hepatitis B e antigen seroconversion while on lamivudine

131 nth course of interferon alfa-2b can achieve hepatitis B e antigen seroconversion, normalization of a

132 t virologic markers of HBV disease activity (hepatitis B e antigen status or HBV DNA level) are assoc

133 rminants of HCC risk include their sex, age, hepatitis B e antigen status, HBV genotype, and levels o

134 ect patients based on age, viral levels, and hepatitis B e antigen status, these clinical and biochem

135 gen-positive patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and abou

136 ted with higher rates of seroconversion from hepatitis B e antigen to hepatitis B e antibody, normali

137 ontribute to accelerated seroconversion from hepatitis B e antigen to its antibody in black South Afr

138 hepatitis B e antigen variants with reduced hepatitis B e antigen translation by a ribosomal leaky s

139 We have identified a novel class of hepatitis B e antigen variants with reduced hepatitis B

140 tis B virus dimers of the same genotype, and hepatitis B e antigen was quantified from culture medium